Medline: The Bill for Taking Share Comes Due in 2027
Sales guidance rose for the third straight quarter, but a first-ever buyback and a low-to-mid-single-digit 2027 EBITDA framework reveal where the margin pressure went.
MDLN · Earnings Call · 2026-11-04
Medline’s third quarter had the shape of a beat-and-raise. Net sales rose 10% to $7.9 billion, adjusted EBITDA rose 12% to $1 billion, and the company lifted full-year organic sales guidance to 10%–10.5% from 9%–10%. It was the third consecutive quarter of upward sales revisions. The stock has noticed: MDLN is up 16.9% over the last 27 trading days into the print. “We delivered another strong quarter with every segment and channel contributing to growth.” — Michael Drazin, Chief Financial Officer · 2026-11-04
But the headline hides the more important number: the 2027 framework. Management expects high-single-digit sales growth next year but only low-to-mid-single-digit adjusted EBITDA growth. That is a sharp deceleration from the 12% EBITDA growth just delivered and implies margin compression, not operating leverage. The company is explicitly choosing to invest through inflation and quality overhang, and it is asking investors to wait for 2028 for the algorithm to normalize.
The tariff refund tailwind is fading from the story
The quarter’s adjusted EBITDA included an $81 million benefit from IEEPA tariff refunds, and net refunds through the third quarter reached $324 million. Management excludes those refunds from guidance, and on the call Mike Drazin was explicit about why: “Our goal is to give you a clear view of the underlying earnings of the business, without the distortion of onetime refund benefits.” — Michael Drazin, Chief Financial Officer · 2026-11-04 The keyword trail confirms the shift. tariff refund was a top-two company keyword last quarter; in the current quarter it has dropped out of the top 30. The new top company keywords are Brand conversion, Quality Action Plan, customer mix, and near term margin pressure. That is management trying to move the narrative from one-time cash to recurring earnings power.
The global tape shows Medline was riding a broader wave. Tariff refunds were a market-wide theme earlier in the year. Now the global keyword list has Supply Chain Solutions as its second-highest momentum phrase — and for Medline, that same segment is the source of the margin problem. Supply Chain Solutions adjusted EBITDA margin was 4.4% in the third quarter, well below the 4.9%–5% guide given just 90 days earlier.
we reported 4.9% adjusted EBITDA margin for the quarter... we're looking at more like 4.9% to 5% adjusted EBITDA for that business.
What changed? New prime vendor signings carry first-year rebates, customer mix is tilting toward lower-margin acute care, and the segment mix is shifting as Supply Chain Solutions outgrows the higher-margin Medline Brand. Drazin conceded the pressure arrived faster than expected: “we have seen a little bit of an acceleration in that front relative to our expectation.” — Michael Drazin, Chief Financial Officer · 2026-11-04 The model still works over a customer’s lifetime — roughly 10% brand conversion in year one, then 2%–4% annually — but the first-year P&L is ugly.
Inflation is no longer assumed transitory
The other change is philosophical. Last quarter, Drazin estimated roughly half the margin impact was transitory and half permanent. This quarter, the Middle East cost estimate rose to $80 million from $70 million, diesel is running near $6.25 a gallon, and the assumption is that elevated raw material and finished-goods costs persist through all of 2027. “previously thought that would be transit in nature, and now we are thinking it may not be so much transitory in nature.” — Michael Drazin, Chief Financial Officer · 2026-11-04 That is a meaningful shift in the cost baseline, and it explains the widening gap between sales growth and EBITDA growth. cost inflation and cost of goods sold are now front-and-center in the company’s own keyword set.
The pricing response is new, too. Jim Boyle has consistently argued that Medline absorbs cost shocks and takes share first, then raises price only when the new cost level looks durable. Last quarter he said: “we don't act in times of uncertainty and chaos and crisis... it's better to absorb and take share than it is to take price that you ultimately have to pull back and give.” — James Boyle, Chief Executive Officer · 2026-08-05 This quarter, Medline announced a larger-than-usual price increase for early in the first quarter of 2027. Boyle framed it carefully: “pricing is not a lever for growth. it is a lever to actually impact real COGS that are impacting the business on a sustainable long term basis.” — James Boyle, Chief Executive Officer · 2026-11-04 In other words, the company has decided the cost base has reset.
It is also restructuring. A program launched in the fourth quarter will cost $20 million–$30 million and generate $80 million–$90 million in annualized savings, mostly in 2027. And for the first time in its public life, Medline authorized a $1 billion share repurchase. return capital is a new entry in the company’s thematic vocabulary. The buyback is backed by real cash: management cited $1.8 billion of free cash flow for the first nine months, $3.6 billion of cash and short-term investments, and net leverage of 2.5x, down from 2.9x. A $750 million term loan prepayment in October followed.
Free cash flow (less SBC) was $575 million in the latest reported quarter, up 96% sequentially and $235 million above the prior-year trend.
The quality overhang is now a line item
The Global Quality Action Plan has moved from a footnote to a top-three company keyword. Medline is running independent assessments across more than 30 manufacturing sites, a multiyear effort that is already reflected in 2026 guidance and the 2027 framework. It also recently exited the home care bed market, a roughly $60 million business, after more than a year of work with the FDA. When asked whether more product exits are coming, Boyle was candid: “Could there be something else? Yes. Do I anticipate there to be something else? No.” — James Boyle, Chief Executive Officer · 2026-11-04 That is not a guarantee, but it is the right way to frame a quality remediation that touches the entire book of business.
The market is paying for 2028, not 2027
The stock’s 17% run into the print suggests investors are looking through the 2027 air pocket to the 2028 recovery, when management expects adjusted EBITDA growth to return to at or above sales growth. The bull case is straightforward: Medline is still taking share, with $1 billion of new customer signings on track, a first prime vendor partnership in Canada live at five hospitals, and four new distribution centers under development. The bear case is that the margin math keeps slipping — if Middle East costs are structural, if quality spending is multiyear, and if Supply Chain Solutions margins stay in the mid-4s, the 2028 inflection could move again.
The buyback is a floor, not a fix. It signals confidence and provides support, but it does not change the fact that the first-year economics of Medline’s land-and-expand model are getting more expensive. The company is doing the right things strategically — investing in automation, capacity, and quality while protecting the customer relationship. But the market is now paying for a margin recovery that has not yet shown up in the numbers.